EurocanPlatform: a European platform for translational cancer research

Our aim is bring together European cancer institutions and to improve outcomes for cancer patients and reduce mortality.

Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analyzed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centers, institutions in which care and prevention is integrated with research and education. Furthermore, it proposed the creation of a platform of interlinked cancer centers with shared infrastructures and collaborative projects to facilitate rapid advances in knowledge, and their translation into better cancer care.

In response to these challenges, EurocanPlatform will work towards the goal of decreasing cancer mortality by focusing on three main areas of strategic research: prevention, early detection and improved treatments. It will build the necessary resources and know-how for the entire research continuum: basic research, early and late translational research, clinical research, epidemiological research, implementation in care and population based outcome research. There will be a strong focus on discovery-driven translational cancer research in five selected tumors: breast, head-neck, lung, malignant melanoma and pancreatic cancer.

EurocanPlatform is an EU-funded project bringing together 28 European cancer institutions and organizations, and is coordinated by Karolinska Institutet (Prof. Ulrik Ringborg, coordinator, and Prof. Rolf Lewensohn, vice-coordinator). Joint structures and programs for early detection will contribute to optimal treatment, and novel prevention research programs will integrate prevention activities in clinical cancer centers as well as public prevention. Collaborations will also include molecular pathway-driven clinical research supported by joint structures for omics, biobanking and biomarker validation to support clinical trials aimed at enhancing patient benefits by individualized treatments.

EurocanPlatform is unique in its nature and represents a commitment from cancer centers to join forces and resources in order to fight cancer.


European Union Seventh Framework Programme (FP7): HEALTH-2010-260791


Eurocan platform